Deutsche Bank Aktiengesellschaft Lowers IQVIA (NYSE:IQV) Price Target to $265.00

IQVIA (NYSE:IQV) had its target price lowered by Deutsche Bank Aktiengesellschaft from $270.00 to $265.00 in a research note issued to investors on Friday morning, Benzinga reports. The firm currently has a buy rating on the medical research company’s stock.

Several other research firms have also issued reports on IQV. TD Cowen reduced their target price on IQVIA from $270.00 to $255.00 and set a “buy” rating on the stock in a report on Friday. Barclays reduced their price objective on shares of IQVIA from $275.00 to $260.00 and set an “overweight” rating on the stock in a research note on Tuesday, October 15th. StockNews.com raised shares of IQVIA from a “hold” rating to a “buy” rating in a report on Wednesday, October 30th. JPMorgan Chase & Co. decreased their price objective on shares of IQVIA from $288.00 to $279.00 and set an “overweight” rating on the stock in a research note on Wednesday, October 23rd. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $270.00 target price on shares of IQVIA in a report on Friday. Four equities research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, IQVIA has a consensus rating of “Moderate Buy” and an average target price of $263.81.

IQVIA Stock Up 1.6 %

NYSE IQV opened at $209.16 on Friday. The company has a 50 day moving average of $234.31 and a 200-day moving average of $229.76. IQVIA has a 1-year low of $181.03 and a 1-year high of $261.73. The company has a current ratio of 0.81, a quick ratio of 0.85 and a debt-to-equity ratio of 1.76. The company has a market cap of $38.13 billion, a price-to-earnings ratio of 27.45, a PEG ratio of 2.01 and a beta of 1.51.

Insider Buying and Selling at IQVIA

In other news, insider Eric Sherbet sold 1,300 shares of the firm’s stock in a transaction dated Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total transaction of $320,229.00. Following the completion of the transaction, the insider now directly owns 19,536 shares in the company, valued at $4,812,302.88. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 1.60% of the company’s stock.

Institutional Investors Weigh In On IQVIA

Several hedge funds and other institutional investors have recently bought and sold shares of IQV. Wealth Enhancement Advisory Services LLC grew its holdings in shares of IQVIA by 5.4% during the first quarter. Wealth Enhancement Advisory Services LLC now owns 5,898 shares of the medical research company’s stock valued at $1,492,000 after buying an additional 300 shares during the last quarter. Norden Group LLC purchased a new stake in IQVIA during the first quarter worth about $703,000. BNP Paribas Financial Markets raised its holdings in shares of IQVIA by 48.4% in the 1st quarter. BNP Paribas Financial Markets now owns 164,147 shares of the medical research company’s stock worth $41,511,000 after purchasing an additional 53,560 shares during the period. Janney Montgomery Scott LLC raised its stake in shares of IQVIA by 3.3% in the first quarter. Janney Montgomery Scott LLC now owns 36,288 shares of the medical research company’s stock valued at $9,177,000 after buying an additional 1,172 shares during the period. Finally, Tokio Marine Asset Management Co. Ltd. raised its stake in IQVIA by 10.2% in the 1st quarter. Tokio Marine Asset Management Co. Ltd. now owns 5,078 shares of the medical research company’s stock valued at $1,284,000 after acquiring an additional 468 shares during the period. 89.62% of the stock is owned by institutional investors.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.